Coronaviridae

Global Smart Syringe Market Forecasts from 2021 to 2026 with COVID-19 Impact and Key Company Developments - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 22, 2021
Health, Medical Supplies, Medical Devices, Vaccination, Pfizer, Hindustan Syringes & Medical Devices, WHO, ML, Becton, Dickinson and Company headquarters, Technology, Inflammation, Gavi, Hepatitis C, Stichting IKEA Foundation, Death, World Health Organization, Hepatitis, World, COVAX, Injection, Government, Collection, COVID-19, Organization, UNICEF, PVC, Coronaviridae, Viral hepatitis, Policy, Population, Hepatitis A, Liver, HIV, Company, Safety, Acceleration, Corona, Syringe, Medical device, Adoption, Vaccine, Infection, Pharmaceutical industry, Animal

The "Smart Syringe Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Smart Syringe Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The rise in the incidences of diseases such as HIV, Hepatitis C, and other infections due to unsafe injection practices is driving the market for smart syringes.
  • Major companies have been making significant developments in the market, in the past few years.
  • For instance, PAL Systems, one of the key players in the market, provides a smart syringe that contains electronic data storage for process safety and the highest precision.

Biotech Sector's Response to Omicron Panic Should be Swift and Effective

Retrieved on: 
Tuesday, December 7, 2021
NYSE, Reuters, PFE, S, Research, Delta, COVID-19, CSE, Technology, JPMorgan Chase, Severe acute respiratory syndrome coronavirus, Pfizer–BioNTech COVID-19 vaccine, Panic, Coronaviridae, NVAX, Wuxi, Safety, Coronavirus, BBC, COVID, RNA transfection, Novavax, Method, Ohio State University, Bloomberg Television, BioNTech, Pandemic, Government, Protein, DTH, FDA, OSU, SE, NASDAQ, MRNA, BNTX, News, Interview, SARS2, Severe acute respiratory syndrome coronavirus 2, Vaccine, Pharmaceutical industry, Animal

"Research suggests that a pan-sarbecovirus vaccine could potentially prevent additional emergent variants and help end the Covid-19 pandemic."

Key Points: 
  • "Research suggests that a pan-sarbecovirus vaccine could potentially prevent additional emergent variants and help end the Covid-19 pandemic."
  • Sarbecoviruses are a subset of the Coronaviridae family, which includes the emerging SARS2 variants Delta and Omicron.
  • BioVaxys recently filed apatent application for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most or all sarbecoviruses.
  • According to Burton, Modernashould know whether their current COVID-19 vaccine can provide protection against Omicron in the "next couple weeks."

Biotech Sector's Response to Omicron Panic Should be Swift and Effective

Retrieved on: 
Tuesday, December 7, 2021
NYSE, Reuters, PFE, S, Research, Delta, COVID-19, CSE, Technology, JPMorgan Chase, Severe acute respiratory syndrome coronavirus, Pfizer–BioNTech COVID-19 vaccine, Panic, Coronaviridae, NVAX, Wuxi, Safety, Coronavirus, BBC, COVID, RNA transfection, Novavax, Method, Ohio State University, Bloomberg Television, BioNTech, Pandemic, Government, Protein, DTH, FDA, OSU, SE, NASDAQ, MRNA, BNTX, News, Interview, SARS2, Severe acute respiratory syndrome coronavirus 2, Vaccine, Pharmaceutical industry, Animal

VANCOUVER, BC, Dec. 7, 2021 /PRNewswire/ -- USA News Group - Despite a level of panic that JP Morgan has already downplayed in its 2022 forecasts, the market's reaction to the latest COVID-19 variant scare (omicron) has been swift. A multitude of reactionary strategies have begun to swirl, including injecting more boosters from the original vaccine, or fast-tracking newly revamped vaccines. As COVID researchers rush to learn about the new variant, the biotech sector is responding in kind, with new developments already underway from companies such as BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Moderna, Inc. (NASDAQ: MRNA), BioNTech SE (NASDAQ: BNTX), and Pfizer, Inc. (NYSE: PFE), as well as Novavax, Inc. (NASDAQ: NVAX).

Key Points: 
  • "Research suggests that a pan-sarbecovirus vaccine could potentially prevent additional emergent variants and help end the Covid-19 pandemic."
  • Sarbecoviruses are a subset of the Coronaviridae family, which includes the emerging SARS2 variants Delta and Omicron.
  • BioVaxys recently filed apatent application for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most or all sarbecoviruses.
  • According to Burton, Modernashould know whether their current COVID-19 vaccine can provide protection against Omicron in the "next couple weeks."

Indoor Air Quality Leader Wynd Launches Air Quality Optimization Service Suite as Employees Return to Office

Retrieved on: 
Monday, December 6, 2021
Consumer Electronics, Medical Devices, Health, Technology, Infectious Diseases, Other Health, Table, MIT, Safety, Environment, Workforce, Technology, AI, VC, Overalls, Coronaviridae, Viral load, Time Magazine Quality Dealer Award, Health, Aerosol, Atmosphere of Earth, Workplace, Software, Time, Research, Pollen, HVAC, Atmosphere, Time (magazine), COVID19, Efficiency, Harvard University, Partner, Multimedia, COVID, Heating, ventilation, and air conditioning

Wynd Technologies, Inc., a California-based maker of proprietary AI-powered indoor air monitoring and purification technologies, has announced the launch of its Indoor Air Quality Optimization Service, a suite of products that simultaneously detect, monitor, and remediate air quality within any built environment.

Key Points: 
  • Wynd Technologies, Inc., a California-based maker of proprietary AI-powered indoor air monitoring and purification technologies, has announced the launch of its Indoor Air Quality Optimization Service, a suite of products that simultaneously detect, monitor, and remediate air quality within any built environment.
  • Wynds Indoor Air Quality Optimization service enables healthy and productive environments for property owners, tenants, and their employees by monitoring and analyzing indoor air quality and continuously purifying air with medical-grade filter systems.
  • The Indoor Air Quality Optimization service comprises the most comprehensive indoor air quality monitoring of health, safety, comfort and productivity in the workplace.
  • Having Wynds Indoor Air Quality monitoring and air purification helps our employees and guests feel and be safer.

Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Retrieved on: 
Monday, November 29, 2021
News, World Health Organization, Regulation of tobacco by the U.S. Food and Drug Administration, Forward-looking statement, Company, Walmart, WHO, World, Level 3, Micron Technology, Health Canada, COVID-19, CSE, Omicron, Risk, Society, Coronaviridae, Medical device, FSE, Canadian Securities Exchange, Food, Printed circuit board, Animal

The World Health Organization (WHO) declared the new variant identified in South Africa, named "Omicron", as a "variant of concern" .

Key Points: 
  • The World Health Organization (WHO) declared the new variant identified in South Africa, named "Omicron", as a "variant of concern" .
  • Micron Technologies has been manufacturing and selling three-ply medical grade Level 3 face masks in Delta, B.C.
  • Micron Technologies is manufacturing three-ply medical grade face masks pursuant its Medical Device Establishment License issued by Health Canada.
  • As previously announced, Micron Technologies' medical grade face masks are available to purchase through Walmart, Amazon and Shopify.

$29 Billion Clinical Trial Supply and Logistics Markets - Global Forecasts from 2021 to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 17, 2021
Health, Clinical Trials, Medical Supplies, Patient, Government, Goldman Sachs, Safety, Coronavirus, Technology, Industry, Acquisition, Sarah Cannon Research Institute, CAGR, Peripheral, Clinical trial, Expansion, Coronaviridae, IMS, R, Research, COVID-19, Parexel, FedEx, Drug development, Growth, EQT, Pharmaceutical industry, Fine chemical

The "Clinical Trial Supply and Logistics Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clinical Trial Supply and Logistics Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global clinical trial supply and logistics market is projected to grow at a CAGR of 8.91% during the forecast period to reach US$29.176 billion by 2026, from US$16.050 billion in 2019.
  • Clinical trial and logistic service providers aim at providing support and equipment for clinical trials to the research institute to yield fruitful results.
  • The vendors in the global clinical trial supply and logistics market are enjoying a significantly high power attributable to the lack of substitutes in the landscape.

New progress of studies on Lianhua Qingwen's mechanism to fight against SARS-CoV-2

Retrieved on: 
Thursday, November 4, 2021
UCPH School of Pharmaceutical Sciences, Traditional Chinese medicine, Research, Technology, Cough, First, HRMS, Huoshenshan Hospital, Influenza A virus, Data mining, Pharmacy, ACE2, School, Second Military Medical University, Urine, Xiamen University, Amygdalin, Severe acute respiratory syndrome coronavirus 2, Prescription, Medicine, Fever, Literature, Coronaviridae, COVID-19, Attention, Leishenshan Hospital, News, Tianjin University, Yiling District, Lianhua Qingwen, Quercetin, Immunomodulation, Influenza B virus, Plasma, Pharmaceutical industry, Vaccine

In addition, with the increasing popularity of the drug, scientists have carried out a series of basic and clinical studies, proving its effectiveness with data evidence.

Key Points: 
  • In addition, with the increasing popularity of the drug, scientists have carried out a series of basic and clinical studies, proving its effectiveness with data evidence.
  • Based on HRMS and intelligent untargeted data mining technology, this study comprehensively analyzes the components of Lianhua Qingwen Capsules in plasma and urine after repeated administration.
  • In this study, TCMSP and TCMID databases as well as related literature are used to screen out the active ingredients and targets of Lianhua Qingwen.
  • During the pandemic, Lianhua Qingwen has been widely used in the mobile cabin hospitals in Wuhan, China, including Huoshenshan Hospital and Leishenshan Hospital.

New progress of studies on Lianhua Qingwen's mechanism to fight against SARS-CoV-2

Retrieved on: 
Thursday, November 4, 2021
UCPH School of Pharmaceutical Sciences, Traditional Chinese medicine, Research, Technology, Cough, First, HRMS, Huoshenshan Hospital, Influenza A virus, Data mining, Pharmacy, ACE2, School, Second Military Medical University, Urine, Xiamen University, Amygdalin, Severe acute respiratory syndrome coronavirus 2, Prescription, Medicine, Fever, Literature, Coronaviridae, COVID-19, Attention, Leishenshan Hospital, News, Tianjin University, Yiling District, Lianhua Qingwen, Quercetin, Immunomodulation, Influenza B virus, Plasma, Pharmaceutical industry, Vaccine

In addition, with the increasing popularity of the drug, scientists have carried out a series of basic and clinical studies, proving its effectiveness with data evidence.

Key Points: 
  • In addition, with the increasing popularity of the drug, scientists have carried out a series of basic and clinical studies, proving its effectiveness with data evidence.
  • Based on HRMS and intelligent untargeted data mining technology, this study comprehensively analyzes the components of Lianhua Qingwen Capsules in plasma and urine after repeated administration.
  • In this study, TCMSP and TCMID databases as well as related literature are used to screen out the active ingredients and targets of Lianhua Qingwen.
  • During the pandemic, Lianhua Qingwen has been widely used in the mobile cabin hospitals in Wuhan, China, including Huoshenshan Hospital and Leishenshan Hospital.

Avrio Health L.P. Announces Publication of In Vitro Test Results Assessing Betadine® Formulations Against Four Coronaviruses

Retrieved on: 
Thursday, October 14, 2021
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Viral load, ASTM, Severe acute respiratory syndrome coronavirus 2, Different, Health, Method, Doctor of Philosophy, Coronaviridae, Knowledge, Master of Science, Bachelor of Pharmacy, Sore throat, Public health, Alphacoronavirus, Science, Betacoronavirus, Infection, OC43, Purdue Pharma, CEO, Povidone-iodine, Safety, MD, NL63, Research, Shet, Virus, Quality of life, Pharmaceutical industry, Medical device

Avrio Health L.P. today announced the publication of results from two in vitro laboratory studies assessing Betadine antiseptic products (active ingredient: povidone-iodine or PVP-I) against four coronaviruses used as a surrogate for SARS-CoV-2.

Key Points: 
  • Avrio Health L.P. today announced the publication of results from two in vitro laboratory studies assessing Betadine antiseptic products (active ingredient: povidone-iodine or PVP-I) against four coronaviruses used as a surrogate for SARS-CoV-2.
  • The studies, published in Infectious Diseases and Therapy , found that Betadine Topical Solution, Betadine Surgical Scrub, and Betadine Gargle demonstrated virucidal activity against the coronaviruses studied.
  • Avrio Health is committed to scientific exploration to help inform health care provider response to public health needs.
  • Betadine Topical Solution (containing 5.0% and 10.0% PVP-I), Betadine Surgical Scrub (containing 7.5% PVP-I), and Betadine Gargle (containing 0.5% PVP-I) were compared to placebo in two separate in vitro studies and showed virucidal activity against four coronaviruses.

Senstar Technologies Completes Name and Ticker Symbol Change

Retrieved on: 
Thursday, September 30, 2021
Coronaviridae, Solution, Annual report, Security (finance), NASDAQ, U.S. Securities and Exchange Commission, Nasdaq, VMS, Company, Growth, Senstar Corporation, COVID19, PIDS, Risk management

Dror Sharon, Chief Executive Officer of Senstar, commented, "Rebranding under the Senstar name conveys our strategic focus on operating as a pure technology-driven, product and solutions company.

Key Points: 
  • Dror Sharon, Chief Executive Officer of Senstar, commented, "Rebranding under the Senstar name conveys our strategic focus on operating as a pure technology-driven, product and solutions company.
  • The Senstar name is widely recognized for innovative, reliable perimeter intrusion detection systems (PIDS) and intelligent video management solutions (VMS) with advanced video analytics and access control.
  • The Company implemented the name and ticker symbol change in conjunction with the divestiture of its Integrated Solutions Division as part of its strategic decision to focus primarily on the Company's product division.
  • Senstar offers a comprehensive suite of proven, integrated technologies that reduce complexity, improve performance and unify support.